James G. Kotsanos, MD, MS

home / authors / james-g-kotsanos-md-ms

Articles

May 1st 1997

Resource Utilization and Work or School Loss Reported by Patients with Diabetes: Experience in Diabetes Training Programs

John C. Licciardone, DO, MBA James G. Kotsanos, MD, MS Valerie Brinkman-Kaplan, MS, RD, CDE Tamara Cooper, RN, CDE Jack E. Jordan, MBA Kathleen L

October 1st 1996

Comparison of a Decision Analytic Model with Results from a Naturalistic Economic Clinical Trial: An Application to Evaluating Alternative Antidepressants

Timothy R. Hylan, PhD James G. Kotsanos, MD, MS John S. Andersen, PhD Susan H. Brown, PhD Catherine Copley-Merriman, MBA, MS Lisa Egbuonu-Davis,

Latest Updated Articles

What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Clinician giving patient a diagnosis | Image Credit: Pcess609 - stock.adobe.com

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Hurricane | Image credit: Satoshi Kina - stock.adobe.com

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Opdivo packaging | Image credit: Bristol Myers Squibb

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Blood smear AML | image credit: Chansom Pantip - stock.adobe.com

Published: October 20th 2024 | Updated: November 8th 2024

FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions